Development and validation of a nomogram based on clinical factors and standard laboratory tests for prediction of clinically significant liver fibrosis in chronic hepatitis C virus infection

Elisabetta Sagrini, Ilaria Ardoino, Giuseppe Marano, Alice Gianstefani, Alessandra Orlandini, Giada Sebastiani, Gabriele Donati, Alessandro Cucchetti, Guido Pelosi, Carlo Ferrari, Alfredo Alberti, Elia Biganzoli, Fabio Piscaglia, Luigi Bolondi

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

OBJECTIVES: Staging liver fibrosis in chronic viral hepatitis C (HCV) patients is essential for prompting surveillance and treatment. The aim of this study was to develop a nomogram, on the basis of simple clinical and laboratory variables, to predict three clinically significant stages of fibrosis (nil-mild, moderate, advanced/cirrhosis), using histology as reference, and to compare its performance with that of FibroTest, a widely used noninvasive fibrosis score. MATERIALS AND METHODS: Nomograms are graphical representations of a mathematical formula, used as predictive tools. The study retrospectively recruited 406 HCV patients undergoing liver biopsy. Nomogram was developed in a training set of 252 patients and tested in a validation set of 154 patients. Histology was staged according to the Metavir system. Fibrosis stages were subgrouped as follows: advanced fibrosis/cirrhosis (F3/F4, 24%), nil-mild (F0/F1, 36%), and moderate (F2, 40%). Age at biopsy, aspartate aminotransferase, γ-glutamyl transpeptidase, albumin, platelet count, and prothrombin activity formed the basis for the so-called Fibro-Nomogram, which, in one graphical representation, estimates probability for different stages of fibrosis. RESULTS: Areas under the receiver-operating characteristic curves for advanced fibrosis/cirrhosis were similar for training (0.86) and validation sets (0.87). For nil-mild fibrosis, area under the receiver-operating characteristics were 0.81 and 0.79. Compared with FibroTest, Fibro-Nomogram performed slightly better at predicting severe fibrosis (F3/F4) with positive likelihood ratio (LR+) 5.07 (95% confidence interval 3.08-8.37) versus LR+ 3.82 (95% confidence interval 2.56-5.71) for FibroTest. For nil-mild fibrosis, the two tests showed limited but comparable performances. CONCLUSION: In HCV patients, Fibro-Nomogram, an inexpensive and readily available predictive tool, could enable clinicians to interpret patients' profile, concurrently stratifying patients into three clinically relevant probability categories with good overall performance.

Original languageEnglish
Pages (from-to)1385-1395
Number of pages11
JournalEuropean Journal of Gastroenterology and Hepatology
Volume25
Issue number12
DOIs
Publication statusPublished - Dec 2013

Fingerprint

Nomograms
Chronic Hepatitis C
Virus Diseases
Hepacivirus
Liver Cirrhosis
Fibrosis
ROC Curve
Histology
Confidence Intervals
Biopsy
gamma-Glutamyltransferase
Prothrombin
Aspartate Aminotransferases
Platelet Count
Albumins

Keywords

  • chronic viral hepatitis C
  • clinical decision making
  • liver fibrosis prediction
  • nomogram

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this

Development and validation of a nomogram based on clinical factors and standard laboratory tests for prediction of clinically significant liver fibrosis in chronic hepatitis C virus infection. / Sagrini, Elisabetta; Ardoino, Ilaria; Marano, Giuseppe; Gianstefani, Alice; Orlandini, Alessandra; Sebastiani, Giada; Donati, Gabriele; Cucchetti, Alessandro; Pelosi, Guido; Ferrari, Carlo; Alberti, Alfredo; Biganzoli, Elia; Piscaglia, Fabio; Bolondi, Luigi.

In: European Journal of Gastroenterology and Hepatology, Vol. 25, No. 12, 12.2013, p. 1385-1395.

Research output: Contribution to journalArticle

Sagrini, E, Ardoino, I, Marano, G, Gianstefani, A, Orlandini, A, Sebastiani, G, Donati, G, Cucchetti, A, Pelosi, G, Ferrari, C, Alberti, A, Biganzoli, E, Piscaglia, F & Bolondi, L 2013, 'Development and validation of a nomogram based on clinical factors and standard laboratory tests for prediction of clinically significant liver fibrosis in chronic hepatitis C virus infection', European Journal of Gastroenterology and Hepatology, vol. 25, no. 12, pp. 1385-1395. https://doi.org/10.1097/MEG.0b013e328363e29d
Sagrini, Elisabetta ; Ardoino, Ilaria ; Marano, Giuseppe ; Gianstefani, Alice ; Orlandini, Alessandra ; Sebastiani, Giada ; Donati, Gabriele ; Cucchetti, Alessandro ; Pelosi, Guido ; Ferrari, Carlo ; Alberti, Alfredo ; Biganzoli, Elia ; Piscaglia, Fabio ; Bolondi, Luigi. / Development and validation of a nomogram based on clinical factors and standard laboratory tests for prediction of clinically significant liver fibrosis in chronic hepatitis C virus infection. In: European Journal of Gastroenterology and Hepatology. 2013 ; Vol. 25, No. 12. pp. 1385-1395.
@article{4357548d23c149618c778067b6232099,
title = "Development and validation of a nomogram based on clinical factors and standard laboratory tests for prediction of clinically significant liver fibrosis in chronic hepatitis C virus infection",
abstract = "OBJECTIVES: Staging liver fibrosis in chronic viral hepatitis C (HCV) patients is essential for prompting surveillance and treatment. The aim of this study was to develop a nomogram, on the basis of simple clinical and laboratory variables, to predict three clinically significant stages of fibrosis (nil-mild, moderate, advanced/cirrhosis), using histology as reference, and to compare its performance with that of FibroTest, a widely used noninvasive fibrosis score. MATERIALS AND METHODS: Nomograms are graphical representations of a mathematical formula, used as predictive tools. The study retrospectively recruited 406 HCV patients undergoing liver biopsy. Nomogram was developed in a training set of 252 patients and tested in a validation set of 154 patients. Histology was staged according to the Metavir system. Fibrosis stages were subgrouped as follows: advanced fibrosis/cirrhosis (F3/F4, 24{\%}), nil-mild (F0/F1, 36{\%}), and moderate (F2, 40{\%}). Age at biopsy, aspartate aminotransferase, γ-glutamyl transpeptidase, albumin, platelet count, and prothrombin activity formed the basis for the so-called Fibro-Nomogram, which, in one graphical representation, estimates probability for different stages of fibrosis. RESULTS: Areas under the receiver-operating characteristic curves for advanced fibrosis/cirrhosis were similar for training (0.86) and validation sets (0.87). For nil-mild fibrosis, area under the receiver-operating characteristics were 0.81 and 0.79. Compared with FibroTest, Fibro-Nomogram performed slightly better at predicting severe fibrosis (F3/F4) with positive likelihood ratio (LR+) 5.07 (95{\%} confidence interval 3.08-8.37) versus LR+ 3.82 (95{\%} confidence interval 2.56-5.71) for FibroTest. For nil-mild fibrosis, the two tests showed limited but comparable performances. CONCLUSION: In HCV patients, Fibro-Nomogram, an inexpensive and readily available predictive tool, could enable clinicians to interpret patients' profile, concurrently stratifying patients into three clinically relevant probability categories with good overall performance.",
keywords = "chronic viral hepatitis C, clinical decision making, liver fibrosis prediction, nomogram",
author = "Elisabetta Sagrini and Ilaria Ardoino and Giuseppe Marano and Alice Gianstefani and Alessandra Orlandini and Giada Sebastiani and Gabriele Donati and Alessandro Cucchetti and Guido Pelosi and Carlo Ferrari and Alfredo Alberti and Elia Biganzoli and Fabio Piscaglia and Luigi Bolondi",
year = "2013",
month = "12",
doi = "10.1097/MEG.0b013e328363e29d",
language = "English",
volume = "25",
pages = "1385--1395",
journal = "European Journal of Gastroenterology and Hepatology",
issn = "0954-691X",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

TY - JOUR

T1 - Development and validation of a nomogram based on clinical factors and standard laboratory tests for prediction of clinically significant liver fibrosis in chronic hepatitis C virus infection

AU - Sagrini, Elisabetta

AU - Ardoino, Ilaria

AU - Marano, Giuseppe

AU - Gianstefani, Alice

AU - Orlandini, Alessandra

AU - Sebastiani, Giada

AU - Donati, Gabriele

AU - Cucchetti, Alessandro

AU - Pelosi, Guido

AU - Ferrari, Carlo

AU - Alberti, Alfredo

AU - Biganzoli, Elia

AU - Piscaglia, Fabio

AU - Bolondi, Luigi

PY - 2013/12

Y1 - 2013/12

N2 - OBJECTIVES: Staging liver fibrosis in chronic viral hepatitis C (HCV) patients is essential for prompting surveillance and treatment. The aim of this study was to develop a nomogram, on the basis of simple clinical and laboratory variables, to predict three clinically significant stages of fibrosis (nil-mild, moderate, advanced/cirrhosis), using histology as reference, and to compare its performance with that of FibroTest, a widely used noninvasive fibrosis score. MATERIALS AND METHODS: Nomograms are graphical representations of a mathematical formula, used as predictive tools. The study retrospectively recruited 406 HCV patients undergoing liver biopsy. Nomogram was developed in a training set of 252 patients and tested in a validation set of 154 patients. Histology was staged according to the Metavir system. Fibrosis stages were subgrouped as follows: advanced fibrosis/cirrhosis (F3/F4, 24%), nil-mild (F0/F1, 36%), and moderate (F2, 40%). Age at biopsy, aspartate aminotransferase, γ-glutamyl transpeptidase, albumin, platelet count, and prothrombin activity formed the basis for the so-called Fibro-Nomogram, which, in one graphical representation, estimates probability for different stages of fibrosis. RESULTS: Areas under the receiver-operating characteristic curves for advanced fibrosis/cirrhosis were similar for training (0.86) and validation sets (0.87). For nil-mild fibrosis, area under the receiver-operating characteristics were 0.81 and 0.79. Compared with FibroTest, Fibro-Nomogram performed slightly better at predicting severe fibrosis (F3/F4) with positive likelihood ratio (LR+) 5.07 (95% confidence interval 3.08-8.37) versus LR+ 3.82 (95% confidence interval 2.56-5.71) for FibroTest. For nil-mild fibrosis, the two tests showed limited but comparable performances. CONCLUSION: In HCV patients, Fibro-Nomogram, an inexpensive and readily available predictive tool, could enable clinicians to interpret patients' profile, concurrently stratifying patients into three clinically relevant probability categories with good overall performance.

AB - OBJECTIVES: Staging liver fibrosis in chronic viral hepatitis C (HCV) patients is essential for prompting surveillance and treatment. The aim of this study was to develop a nomogram, on the basis of simple clinical and laboratory variables, to predict three clinically significant stages of fibrosis (nil-mild, moderate, advanced/cirrhosis), using histology as reference, and to compare its performance with that of FibroTest, a widely used noninvasive fibrosis score. MATERIALS AND METHODS: Nomograms are graphical representations of a mathematical formula, used as predictive tools. The study retrospectively recruited 406 HCV patients undergoing liver biopsy. Nomogram was developed in a training set of 252 patients and tested in a validation set of 154 patients. Histology was staged according to the Metavir system. Fibrosis stages were subgrouped as follows: advanced fibrosis/cirrhosis (F3/F4, 24%), nil-mild (F0/F1, 36%), and moderate (F2, 40%). Age at biopsy, aspartate aminotransferase, γ-glutamyl transpeptidase, albumin, platelet count, and prothrombin activity formed the basis for the so-called Fibro-Nomogram, which, in one graphical representation, estimates probability for different stages of fibrosis. RESULTS: Areas under the receiver-operating characteristic curves for advanced fibrosis/cirrhosis were similar for training (0.86) and validation sets (0.87). For nil-mild fibrosis, area under the receiver-operating characteristics were 0.81 and 0.79. Compared with FibroTest, Fibro-Nomogram performed slightly better at predicting severe fibrosis (F3/F4) with positive likelihood ratio (LR+) 5.07 (95% confidence interval 3.08-8.37) versus LR+ 3.82 (95% confidence interval 2.56-5.71) for FibroTest. For nil-mild fibrosis, the two tests showed limited but comparable performances. CONCLUSION: In HCV patients, Fibro-Nomogram, an inexpensive and readily available predictive tool, could enable clinicians to interpret patients' profile, concurrently stratifying patients into three clinically relevant probability categories with good overall performance.

KW - chronic viral hepatitis C

KW - clinical decision making

KW - liver fibrosis prediction

KW - nomogram

UR - http://www.scopus.com/inward/record.url?scp=84887084388&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887084388&partnerID=8YFLogxK

U2 - 10.1097/MEG.0b013e328363e29d

DO - 10.1097/MEG.0b013e328363e29d

M3 - Article

C2 - 23839163

AN - SCOPUS:84887084388

VL - 25

SP - 1385

EP - 1395

JO - European Journal of Gastroenterology and Hepatology

JF - European Journal of Gastroenterology and Hepatology

SN - 0954-691X

IS - 12

ER -